|
業務類別
|
Biotechnology |
|
業務概覽
|
Electra Therapeutics Inc is a late clinical-stage biopharmaceutical company focused on pioneering a new class of precision medicines for the treatment of immune-mediated diseases and cancer. The company's pipeline includes Ipsoprubart and ELA822. |
| 公司地址
| 230 E Grand Avenue, Suite S-100, South San Francisco, CA, USA, 94080 |
| 電話號碼
| +1 888 743-2290 |
| 傳真號碼
| -- |
| 公司網頁
| https://www.electra-therapeutics.com |
| 員工數量
| 46 |
| Ms. Quehuong Dong, M.B.A. |
Director, President and Chief Executive Officer |
-- |
28/08/2026 |
| Mr. Chris Clark, C.F.A. |
Chief Financial Officer |
-- |
28/08/2026 |
| Dr. Kim-Hien Dao, PhD |
Chief Medical Officer |
-- |
28/08/2026 |
| Dr. Gary S. Koe, PhD |
Chief Technical Officer |
-- |
28/08/2026 |
| Dr. Graham Parry, PhD |
Chief Scientific Officer |
-- |
28/08/2026 |
|
|
| Dr. Beth C. Seidenberg,M.D. |
Independent Director |
28/08/2026 |
| Dr. Carl L. Gordon, C.F.A.,PhD |
Independent Director |
28/08/2026 |
| Mr. Matthew K. Fust, M.B.A. |
Independent Director |
28/08/2026 |
| Dr. Nancy E. Stagliano, PhD |
Chairman of the Board |
28/08/2026 |
| Ms. Quehuong Dong, M.B.A. |
Director, President and Chief Executive Officer |
28/08/2026 |
| Dr. Thomas Geninatti, PhD |
Independent Director |
28/08/2026 |
|
|
|
|